Chlorpromazine

Sold as Thorazine. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Chlorpromazine (sold as Thorazine), first approved Nov 20, 1957, with 0 new uses approved and 0 published complete response letters.

First approved: Nov 20, 1957
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $46.3M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Chlorpromazine HCl	Part D	$46.3M	-12%	36,654
Chlorpromazine HCL	Part B	$0K	+43%	14

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

CHLORPROMAZINE 10 MG TABLET: $0.242 per unitGeneric · -9% in a year
CHLORPROMAZINE 100 MG TABLET: $0.466 per unitGeneric · -42% in a year
CHLORPROMAZINE 200 MG TABLET: $0.664 per unitGeneric · -48% in a year
CHLORPROMAZINE 25 MG TABLET: $0.329 per unitGeneric · -11% in a year
CHLORPROMAZINE 50 MG TABLET: $0.399 per unitGeneric · -36% in a year

Clinical Trials

4 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.Acute Ischemic Stroke · Ji Xunming,MD,PhD	Not applicable	Not yet recruiting	Jan 23, 2026
Study on Hibernation-like Therapy Based on Mechanical ThrombectomyAcute Ischemic Stroke · Capital Medical University	Phase 1	Recruiting	Oct 29, 2024
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing StrategyDelirium, Epileptics · M.D. Anderson Cancer Center	Phase 2 / Phase 3	Recruiting	Jun 24, 2022
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent CancerAdvanced Malignant Neoplasm, Delirium · M.D. Anderson Cancer Center	Phase 2 / Phase 3	Active, not recruiting	Jan 16, 2017

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Nov 20, 1957	ThorazineNDA 9149 · New molecular entity	Glaxosmithkline	4	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA